A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

333

Participants

Timeline

Start Date

May 29, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

March 22, 2026

Conditions
Diabetic Macular Edema
Interventions
DRUG

8 mg aflibercept (BAY 86-5321) (High Dose)

High-dose (HD) aflibercept is the sponsor's study intervention under investigation. Dose formulation: solution in vial. Unit dose strength: 114.3 mg/mL, Dosage Level: 8 mg (70 µL), Route of Administration: Intravitreal (IVT) injection every 16 weeks following 3 initial monthly doses. Packaging/ Labeling: Study Intervention will be provided in sterile 3 mL glass vials. Each vial will be labeled as required per country requirement.

DRUG

2 mg aflibercept (EYLEA, BAY 86-5321)

"Aflibercept 2 mg is the sponsor's active comparator. Dose formulation: solution in vial. Unit dose strength: 40 mg/mL, Dosage Level: 2 mg (50 µL), Route of Administration: Intravitreal (IVT) injection every 8 weeks following 5 initial monthly doses. Packaging/ Labeling: Study Intervention will be provided in sterile 2 mL glass vials. Each vial will be labeled as required per country requirement. Aflibercept 2 mg for the non-study fellow eye treatment is considered an auxiliary medicinal product (AxMP) in this study. Fellow eye treatment will be allowed with 2 mg aflibercept, at the investigator's discretion for indications approved by governing authorities. The treated fellow eye will not be considered an additional study eye."

OTHER

Sham

"To preserve masking, sham injections will be performed for all participants at treatment visits in which participants do not receive an active injection through Week 56. Sham kits will be assigned for visits requiring sham injections. The sham kits are empty but should be handled in the same way as the active study intervention kits.~Sham injections will be given on visits when an active injection is not planned. During the study treatment period all participants will receive either an active injection (8 mg or 2 mg aflibercept) or a sham injection (for masking purposes) following their assigned treatment group and eligibility for Dose regimen modification (DRM)."

Trial Locations (52)

0

Tseung Kwan O Hospital, Tseung Kwan O

100000

Beijing Aier Intech Eye Hospital, Beijing

100050

Beijing Friendship Hospital, Capital Medical University, Beijing

100062

Capital Medical University (CMU) - Beijing Tongren Hospital, Beijing

100730

Beijing Hospital, Beijing

110034

Shenyang He Eye Specialist Hospital, Shenyang

110082

The Fourth People's Hospital of Shenyang, Shenyang

130000

The Second Hospital of Jilin University, Changchun

130061

The First Hospital of Jilin University, Changchun

150001

The First Affiliated Hospital of Harbin Medical University, Harbin

200041

Shanghai eye disease prevention and control center, Shanghai

200080

Shanghai General Hospital, Shanghai

200092

Shanghai Jiao Tong University School of Medicine (SJTUSM) - XinHua Hospital, Shanghai

200126

Eye & Ent Hospital of Fudan University, Shanghai

210006

Nanjing First Hospital, Nanjing

226006

Affiliated hospital of Nantong university, Nantong

230601

The Second Hospital of Anhui medical university, Hefei

250021

Jinan Second People's Hospital, Jinan

250299

Eye hospital of Shandong First Medical University, Jinan

Shandong University of Traditional Chinese Medicine Affiliated Ophthalmology Hospital, Shandong

261041

Weifang Ophthalmology Hospital, Shandong

300384

Tianjin Medical University Eye Hospital, Tianjin

310003

Zhejiang University School of Medicine - The Second Affiliated Hospital, Hangzhou

317099

Taizhou Hospital of Zhejiang Province, Taizhou

325027

Eye Hospital of Wenzhou Medical University, Wenzhou

330006

The First Affiliated Hospital of NanChang University, Nanchang

330200

The Second Affiliated Hospital of Nanchang University, Nanchang

400042

The First Affiliated Hospital of Chongqing Medical Universit, Chongqing

410007

Central South University - The Second Xiangya Hospital, Changsha

430040

Renmin Hosp., Wuhan Univ., Wuhan

450008

Henan Provincial Eye Hospital, Henan

450015

Zhengzhou Second People's Hospital, Erqi

471002

Luoyang Third People's Hospital, Luoyang

510120

Guangdong Provincial Hospital of TCM, Guangzhou

510180

Guangzhou First People Hospital, Guangzhou

510280

Zhujiang Hospital of Southern Medical University, Guangzhou

510288

Guangzhou Aier Ophthalmology Hospital, Guangzhou

515041

Joint Shantou International Eye Center (JSIEC)Shantou University & the Chinese University of Hong Kong, Shantou

530021

The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning

610041

Chengdu Aier Ophthalmology Hospital, Chengdu

610072

Chengdu University of Traditional Chinese Medicine - Teaching Hospital (Sichuan Province Traditional Chinese Medicine Hospital), Chengdu

710005

Xi'an People's Hospital (Xi'an Fourth Hospital), Xi'an

712099

Xianyang First People's Hospital, Xianyang

730030

Lanzhou University Second Hospital, Lanzhou

750002

People's Hospital of Ningxia Hui Autonomous Region - Opthalmology, Ningxia

Unknown

Aier Eye Hospital (LIAONING), Shenyang

030032

Shanxi Bethune Hospital, Taiyuan

MISSING

Sichuan University West China Hospital, Chengdu

050010

Hebei eye hospital, Hebei

030002

Shanxi Eye Hospital, Shanxi

050011

Shijiazhuang People's Hospital, Shijiazhuang

Hong Kong

Grantham Hospital, Hong Kong

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Bayer

INDUSTRY